1197161-07-1

Basic information

• Product Name: 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline
• Synonyms: 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline
• CAS NO: 1197161-07-1
• Molecular Weight: 315.375
• Mol File: 1197161-07-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline(1197161-07-1)
• EPA Substance Registry System: 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline(1197161-07-1)

Safety Data

• Hazardous Substances Data: 1197161-07-1(Hazardous Substances Data)

Upstream product

• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 1197161-06-0 4-(chloro-6-isopropoxy-1,2,3-triazin-2yl)morpholine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1197162-28-9 N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-methylbenzamide 
• 1197161-09-3 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea 
• 1197162-30-3 N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzamide 
• 1197161-08-2 methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate 

Relevant articles and documents

TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS

Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS

Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.